Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597568 | 1.00 | HTT (0.35) | HTTCHRM3TSHRCNR1CNR2 | |
| SCHEMBL7024922 | 0.94 | CHRM3 (0.38) | HTTCHRM3KDM4EPIK3CDL3MBTL1 | |
| SCHEMBL21870608 | 0.94 | CHRM3 (0.38) | HTTCHRM3KDM4EPIK3CDL3MBTL1 | |
| SCHEMBL10808055 | 0.94 | CHRM3 (0.38) | HTTCHRM3KDM4EPIK3CDL3MBTL1 | |
| SCHEMBL8234850 | 0.87 | CYP1A2 (0.33) | HTTCHRM3TSHRCNR1CNR2 | |
| SCHEMBL12039756 | 0.84 | SLC6A9 (0.38) | CHRM3TSHRCNR1CNR2CYP1A2 | |
| SCHEMBL17207528 | 0.84 | TSHR (0.45) | TSHRKDM4E | |
| SCHEMBL27284632 | 0.82 | KMT2A (0.43) | CHRM3CNR1CNR2KDM4EL3MBTL1 | |
| SCHEMBL27282864 | 0.82 | KMT2A (0.43) | CHRM3CNR1CNR2KDM4EL3MBTL1 | |
| SCHEMBL13981439 | 0.82 | KMT2A (0.43) | CHRM3CNR1CNR2KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335672-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335672-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335672-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | HTT 2811/4885CHRM3 318/4885TSHR 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.